FluxMPS™ Basal Medium Eagle (BME): 1X Liquid

FluxMPS™ Basal Medium Eagle (BME), 1X Liquid

FluxMPS™ Basal Medium Eagle (BME), 1X Liquid is an MPS-grade, ultra-filtered cell culture medium manufactured through a proprietary Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2), delivering approximately 5× cleaner media than conventional 0.22 µm-filtered formulations by particulate count. Engineered for microfluidic channels, organ-on-a-chip (OoC), and microphysiological system (MPS) platforms where sub-micron particulates cause sensor drift, microchannel occlusion, and compromised cell viability.

• Quadruple-stage nanofiltration: 0.1 µm pre-filter ×2 + 0.04 µm sterile filter ×2 — the industry’s most rigorous filtration stack for ready-to-use basal media
• Ultra-low endotoxin: < 0.05 EU/mL (USP <85> BET-verified), eliminating TLR4-mediated inflammatory artifacts in sensitive primary cell models
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm), reducing metal ion and organic impurity backgrounds
• ISO Class 5 (Class 100) aseptic fill & finish under ISO 13485:2016 QMS — traceable lot release
• Phenol Red indicator formulation
• Microchannel-safe: USP <788> Method 2 particulate specification — ≤300 particles ≥10 µm/mL, ≤90 particles ≥25 µm/mL
• Custom formulations available — pH, glucose, HEPES, salts, and nutrient modifications on request

Engineered where standard media fails

Conventional 0.22 µm-filtered Basal Medium Eagle passes mycoplasma-sized particles (200–300 nm), sub-visible aggregates, and endotoxin fragments that clog microfluidic channels, trigger innate immune responses, and corrupt downstream biosensor or TEER signals. FluxMPS™ BME closes these failure modes with a four-stage nanofiltration cascade and ISO Class 5 manufacturing — delivering the only ready-to-use BME formulation validated for MPS and organ-on-a-chip platforms.^[1,2]

Quadruple-stage filtration system

FluxMPS™ BME is the only ready-to-use Basal Medium Eagle manufactured through a four-stage nanofiltration cascade terminating at 0.04 µm — a pore size 5.5× smaller than industry-standard 0.22 µm membranes. Each stage serves a distinct purification function, delivering cumulative removal of particulates, bacteria, and mycoplasma-scale contaminants that accumulate in conventional media preparations.

1. 1

   0.1 µm Pre-filtration I — Large Particulate Removal

   First-pass removal of large aggregates, cell debris, and macro-particulates. Extends downstream membrane life and reduces bioburden load before nanofiltration stages.

2. 2

   0.04 µm Pre-filtration II — Sub-Mycoplasma Polishing

   Fine particulate, bacterial, and mycoplasma-sized contaminant retention. The 40 nm pore size provides a sterilizing barrier far below the 200–300 nm size range of mycoplasma organisms.

3. 3

   0.1 µm Sterile-filtration I — Redundancy Pass

   Second-pass 0.1 µm sterile filtration provides process redundancy, ensuring no breakthrough from the first stage propagates forward. Mandatory for ISO Class 5 certified fill lines.

4. 4

   0.04 µm Sterile-filtration II — Final Polish & Aseptic Fill

   Ultimate 40 nm polish immediately prior to ISO Class 5 aseptic fill. Guarantees the lowest achievable sub-visible particulate count and provides the sterilizing assurance required for MPS-grade release.

Optimized for next-generation cell platforms

FluxMPS™ BME’s ultra-clean formulation, precise ionic balance, and microchannel-safe particulate profile make it the ideal basal medium for high-demand research platforms — from organ-on-a-chip perfusion systems to high-resolution metabolomics and live-cell optical sensing.^[1,4,6]

Automated Bioreactors & Robotics

For automated perfusion bioreactors, robotic liquid-handling platforms, and high-throughput microfluidic screening systems, an optional 0.01 µm (10 nm) ultra-filtered variant of FluxMPS™ BME is available. This advanced grade provides near-absolute exclusion of nanoparticulates, protecting precision valves, flow sensors, and sub-micron microchannels from fouling during extended automated runs.

• Total Particulate Exclusion: 0.01 µm filtration removes nanoparticulates that transit standard 0.04 µm membranes, eliminating cumulative fouling in long-duration perfusion experiments
• Valve & Sensor Protection: Ultra-clean media extends the operational lifetime of microfluidic valves, pressure transducers, and optical flow sensors in automated bioreactor systems
• Extended Perfusion Stability: Reduced particulate and endotoxin load sustains baseline-stable TEER, impedance, and biosensor readings across multi-week perfusion protocols

Inquiry Required: The 0.01 µm (10 nm) grade is produced on a project basis. To request this specification, contact support@diagnocine.com.

Analytical & quality release data

Each lot of FluxMPS™ BME is released against a comprehensive Certificate of Analysis covering physical, chemical, sterility, and particulate parameters. All specifications are measured by validated USP and ISO methods, with full traceability to raw material lots.

Full composition (mg/L)

Complete formulation of FluxMPS™ Basal Medium Eagle (BME), 1X Liquid. All values in mg/L; CAS numbers provided for reference. Every ingredient is released per-lot against this specification. Custom adjustments to any component — including L-Glutamine, HEPES, glucose, or salt concentrations — are available on request.

Built under the most rigorous standards in life science

FluxMPS™ BME is manufactured in Totowa, NJ, USA under an ISO 13485:2016 Quality Management System with 21 CFR Part 820 (cGMP) alignment. Every production step — from raw material receipt through final aseptic fill — is documented, traceable, and independently verified.

How FluxMPS BME compares

FluxMPS™ BME is benchmarked below against conventional 0.22 µm single-pass filtered BME formulations from standard suppliers. The differences are most consequential in microfluidic, MPS, and high-sensitivity assay contexts.

Frequently asked questions

Common questions about FluxMPS™ Basal Medium Eagle (BME), 1X Liquid — filtration, formulation, supplementation, and quality assurance.

Supporting literature

Peer-reviewed publications supporting the use of ultra-filtered, MPS-grade basal media in organ-on-a-chip, microfluidic perfusion, metabolomics, vascular biology, and live-cell imaging applications.

1. Huh D, Hamilton GA, Ingber DE. From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011;21(12):745–754.doi:10.1016/j.tcb.2011.09.005
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–772.doi:10.1038/nbt.2989
3. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.doi:10.1126/science.1160809
4. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8(10):839–845.doi:10.1038/nrm2236
5. van der Meer AD, van den Berg A. Organs-on-chips: breaking the in vitro impasse. Integr Biol. 2012;4(5):461–470.doi:10.1039/c2ib00176d
6. Beebe DJ, Ingber DE, den Toonder J. Organs on Chips 2013. Lab Chip. 2013;13(18):3447–3448.doi:10.1039/c3lc90080k
7. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676.doi:10.1016/j.cell.2006.07.024
8. Metallo CM, Vander Heiden MG. Understanding metabolic regulation and its influence on cell physiology. Mol Cell. 2013;49(3):388–398.doi:10.1016/j.molcel.2013.01.018
9. Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-chip: a fast track for engineered human tissues in drug development. Cell Stem Cell. 2018;22(3):310–324.doi:10.1016/j.stem.2018.02.011
10. Zhang YS, Aleman J, Shin SR, et al. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci USA. 2017;114(12):E2293–E2302.doi:10.1073/pnas.1612906114